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1. Einleitung  
1.1 Thyroid cancer  
Thyroid cancer is one of the most common endocrine malignancy [1]. According to the 
American Cancer society there where an estimated 56,870 new cases of thyroid cancer in the 
United States in 2017. In Europe the incidence of thyroid cancer is estimated with 52956 cases, 
with a mortality rate of 6336 patients per year [1].  
Thyroid cancer is classified as differentiated thyroid carcinoma (DTC), anaplastic thyroid 
carcinoma (ATC) and medullary thyroid carcinoma (MTC). DTC includes papillary (80%), 
follicular (10% - 15%) and Hurthle cell carcinomas [2].  
DTCs are the most common pathological entities of thyroid carcinomas. A curative treatment 
with adequate surgical management, radioactive iodine 131-I therapy (RAI) and TSH-
suppressive therapy is possible for most patients [2]. However, for DTC patients with distant 
metastasis or refractoriness to RAI the overall survival rate drops to 10 % at 10 years [3]. Over 
the last couple of years several tyrosine kinase inhibitors have been approved by the EMA and 
FDA as a new effective therapeutic option for patients with progressive, radioiodine-resistant, 
unresectable DTC. Lenvatinib represents one of these new therapeutic options and was approved 
by the FDA (Food and Drug Administration) and EMA (European Medicines Agency) in 2015.  
Less than 5% of all thyroid cancers are represented by MTCs [4]. For patients with metastatic 
disease the 10-year survival rate is 40 to 50% [4]. The results of either single chemotherapy or 
combinations of chemotherapies have shown no clinical benefit or improvement of the 
progression-free survival (PFS) [5]. Thyrosine kinase inhibitors are a new important therapeutic 
option. For the treatment of MTC cabozantinib has been approved by the FDA in 2012 and by 
the EMA in 2014. Vandetanib has also been approved for the treatment of MTC [6].  
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1.2 Lenvatinib  
A randomised, double-blinded and multicenter phase III study recruited patients with progressive 
thyroid cancer that was refractory to 131iodine and randomly assigned 261 patients to receive 
lenvatinib (at a daily dose of 24 mg/d in 28-day cycles) and 131 patients to receive placebo. 
Compared with placebo, lenvatinib was associated with significant improvements in progression- 
free survival and the response rate for patients with 131iodine– refractory thyroid cancer [7]. 
During the 13.8 months of median duration of treatment, treatment-related adverse events (all 
grades) occurred in 97.3% in the lenvatinib group, of these 75.9% were treatment-related adverse 
events of grade 3 or higher [7].  
The phase III study reported treatment-related AEs of any grade in ≥ 10.0% of the patients 
including: hypertension (67.8%), diarrhoea (59.4%), fatigue or asthenia (59.0%), decreased 
appetite (50.2%), decreased weight (46.6%). AEs that led to treatment discontinuation were 
reported in 14.2% of patients receiving lenvatinib. Renal AEs were rare. However, renal failure, 
including acute renal failure of all grades occurred in 4.2% of patients [7]. Grade 3 (CTCAE) 
proteinuria (urinary protein ≥ 3.5 g / 24h) was found in 10.0% of the lenvatinib and none of the 
placebo patients. A proteinuria screening with dose reductions or treatment discontinuation in 
case of an overt proteinuria was part of this trial [7].  
Arterial thromboembolic events were reported in 3.0% of lenvatinib-treated patients and 1.0% in 
the placebo group. Most of the patients had predisposing factors. Only 1 myocardial infarct was 
reported during the 13.8 months of median duration of treatment in the lenvatinib phase III study 
[7]. Prior to lenvatinib sorafenib was approved for the treatment of radioiodine resistant thyroid 
cancer.  
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1.3 Cabozantinib  
A randomised, double-blind Phase III study of cabozantinib for MTC involved 330 patients with 
metastatic MTC comparing cabozantinib 140 mg/day with placebo. A statistically significant 
improvement in estimated median progression-free survival was seen in the cabozantinib group 
(11.2 months) versus placebo (4.0 months) [8]. Adverse events (AEs) of all grades that were 
reported in ≥ 10.0% of the patients in the phase III study with cabozantinib included diarrhoea 
(63.1%), palmar-plantar erythrodysesthesia (50.0%), decreased weight (47.7%), decreased 
appetite (45.8%), nausea (43.0%), fatigue (40.7%). Rare but potentially life-threatening AEs 
including haemorrhage, gastrointestinal perforations, fistula development were observed. In 
16.0% of patients AEs led to discontinuation of the study treatment. Regarding to renal toxicity 
no adverse events have been reported [8].  
1.4 Rationale  
Both phase III trials of cabozantinib and lenvatinib reported that renal adverse events occurred in 
rare cases. The phase III study of cabozantinib reported no adverse events regarding renal 
toxicity. In the lenvatinib phase III trial grade 3 (CTCAE) only proteinuria (urinary protein ≥ 3.5 
g / 24h) was found in 10.0% of the lenvatinib and 0.0% of the placebo patients. No aggravation 
of known mild chronic renal insufficiency (KDOQI stadium 2) during the treatment with 
lenvatinib were reported and no concerning comedications were identified.  
The publication „Anti VEGF-TKI treatment and new renal adverse events not reported in phase 
III trials“ deals with 2 severe adverse events of anti-VEGF tyrosine kinase inhibitor treatment 
that were not reported in the phase III trials. The case reports identify predisposing conditions 
like known mild chronic renal insufficiency with only mild proteinuria and generalised 
atherosclerosis or precipitating co-medications like zolendronate infusion as important risk 
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factors that need to be accounted for in order to prevent the severe adverse renal events 
encountered in our patients.  
Compulsory registries for adverse events not reported in phase III trials and national tumour 
boards like TUTYREF could help to mitigate severe adverse events to these rapidly evolving and 
expensive drugs. 
The manuscript „Myocardial infarction after long-term treatment with a tyrosine kinase inhibitor 
(TKI) with anti-VEGF receptor activity“ reports a patient with papillary thyroid cancer who 
suffered from a myocardial infarction during long-term treatment with lenvatinib. This case 
cautions that long-term treatment with lenvatinib can be associated with myocardial infarction 
also in patients who were asymptomatic and had no predisposing diseases except well controlled 
hypertension and a positive family history for cardiovascular diseases.  
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1.5 Patients 
1.5.1 Renal adverse events  
Patient 1 - cabozantinib  
A 23 year old patient with metastatic medullary thyroid cancer was treated with 4.4 GBq Y-90- 
DOTATATE 10 months after surgery because of progressive MTC. Five months following 
treatment with 4.4 GBq Y-90-DOTATATE, the patient was enrolled in the phase III study 
comparing cabozantinib to placebo. He received blinded treatment for 3 weeks. His creatinine 
was normal (62 µmol/l 30 days before the treatment, 66 µmol/l first day of the treatment). Also 
he showed a normal estimated glomerular filtration (eGFR) rate after CDK-EPI > 90ml/min/1.73 
m2 (KDOQI stadium 1) on the 1st day of the study treatment. Due to bone metastases the patient 
received two times 4 mg zoledronate. Shortly after a 3rd zoledronate infusion the patient 
developed vomiting which did not occur with prior zoledronate infusions before the initiation of 
the study treatment with cabozantinib. 16 days after his enrolment in the study and 11 days 
following the 3rd zoledronate treatment, a creatinine of 150.4 µmol/l and a hypoproteinemia was 
detected. His eGFR after CDK-EPI was 45-59 ml/min/1.73 m2 (KDOQI stadium 3a). 
Subsequently, the patient developed hyperkalemia (6.3 mmol/l), LDH of 525 U/l, anemia, 
thrombocytopenia (76 / nl) and nephrotic range proteinuria of up to 25415 mg / 24h urine 
collection. Renal biopsy on day 30 revealed severe diffuse glomerular thrombotic 
microangiopathy of the VEGF-inhibitor associated type with podocyte damage. Although 
microangiopathic hemolytic anemia with thrombocytopenia ameliorated after 3 plasmapheresis 
treatments, his renal function showed no improvement. The patient was discontinued from study 
treatment. Unfortunately, 4 months after his study enrolment, the patient received his first 
hemodialysis and died because of progressive MTC 262 days after his enrolment in the study.  
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Patient 2 - lenvatinib  
A 67 year old patient with metastatic, papillary thyroid carcinoma was treated with total 
thyroidectomy, followed by 3 radioiodine therapies with a total activity of 20 GBq. Because of 
progressive radioiodine resistant disease 6 years after total thyroidectomy the patient was 
enrolled in the double-blinded phase III study with lenvatinib versus placebo. Of note, the patient 
also suffered from long term arterial hypertension and coronary heart disease with myocardial 
infarction 8 years before study inclusion. He presented a KDOQI stadium 2 prior to the study 
introduction with an eGFR (CDK-EPI) of 60 - 89 ml/min/1.73 m2. There was spurious 
proteinuria assessed by an urine dip stix at study entry. Nevertheless, he fulfilled the study 
inclusion criteria and the criteria for the treatment with lenvatinib. During the study instable 
angina led to coronarography with stenting. During this and further coronarographies he received 
140 ml of imeron 36 days after study entry and 46 ml of ultravist 370 on days 157 and 234 after 
study entry. Subsequently, the patient’s creatinine rose to 143 µmol/l. Renal ultrasonography 
determined kidney lengths of 9.8 and 9.7 cm most likely due to chronic (formerly inadequately 
controlled) longterm arterial hypertension. His creatinine rose further to 218 µmol/l and 
presented a KDOQI stadium 4 with an eGFR (CDK-EPI) of 15 - 29 ml/min/1.73 m2 on day 281 
after study entry. Therefore, lenvatinib was discontinued 279 days after study initiation. Serum 
creatinine declined to 142 µmol/l. After further applications of 85 ml and 110 ml imeron for 
coronary angiography and femoral angioplasty 59 and 131 days after discontinuation of 
lenvatinib respectively, his last creatinine was 177 µmol/l 264 days after discontinuation of 
lenvatinib. The patient died because of a cerebral infarction 708 days after his enrolment in the 
study.  
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1.5.2 Cardiovascular adverse events  
Patientin 3 - lenvatinib  
We report a 73-year old female patient with metastatic thyroid papillary carcinoma who was 
treated with total thyroidectomy. The operation was followed by 4 radioiodine therapies over a 
period of 6 years. At 6 years she developed lung metastasis without radioiodine uptake. 1 year 
after the first diagnosis of radioiodine resistant lung metastasis the lung metastasis showed 
progression according to RECIST criteria [9]. The patient was therefore enrolled in the phase III 
study comparing lenvatinib to placebo. After the study ended the patient was unblinded. 
Lenvatinib treatment resulted in prolonged partial response with disappearance of a hepatic 
metastasis. During further treatment with lenvatinib with dose reduction from initially 24 to 10 
mg at 17 months of lenvatinib treatment a myocardial infarction occurred after 39 months of 
lenvatinib treatment resulting in implantation of 3 stents and a two chamber pacemaker. 
Treatment with lenvatinib was discontinued at the time of diagnosis of the myocardial infarction. 
Except for well controlled hypertension there were neither predisposing diseases like diabetes 
nor symptoms of cardiac ischemia on exertion. Quarterly repeated echocardiography at rest 
showed normal results during the first 2 years of lenvatinib treatment during the phase III study. 
However, the family history for cardiovascular diseases was positive for cardiac infarction 
reported for 1 brother. Another brother was treated for hypertension and the patients mother 
suffered from a cerebral infarction at the age of 60.  
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2. Publikationen 
2.1 Anti VEGF-TKI treatment and new renal adverse events not published in the phase III 
trials 
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What Is Known about This Topic? 
• Both phase III trials of cabozantinib and lenvatinib reported that renal adverse events occurred in rare 
cases. The phase III study of carbozantinib reported no adverse events (AEs) regarding renal toxicity. 
In the lenvatinib phase III trial grade 3 (CTCAE), only proteinuria (urinary protein ≥3.5 g/24 h) was 
found in 10.0% of the lenvatinib and 0.0% of the placebo patients. No aggravation of known mild 
chronic renal insufficiency (KDOQI stage 2) under the treatment with lenvatinib and no concerning 
co-medications were reported.
What Does This Case Report Add?
• We report two severe AEs of anti-VEGF tyrosine kinase inhibitor treatment which were not reported 
in the phase III trials. Our case reports identify predisposing conditions like known mild chronic renal 
insufficiency with only mild proteinuria and with generalized atherosclerosis or precipitating co-med-
ications like zolendronate infusion as important risk factors that need to be accounted for to prevent 
severe adverse renal events encountered in our patients. Compulsory registries for AEs not reported 
in phase III trials and national tumor boards like TUTYREF could help mitigate severe AEs to these 
rapidly evolving and expensive drugs.
DOI: 10.1159/000491387
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Abstract
Cabozantinib and lenvatinib have been approved for the 
treatment of progressive medullary thyroid cancer and ra-
dioiodine-resistant thyroid cancer, respectively. Both phase 
III trials of cabozantinib and lenvatinib reported that renal 
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adverse events (AEs) rarely occurred. The cabozantinib 
phase III study reported no AEs related to renal toxicity. In 
the lenvatinib phase III trial grade 3 (CTCAE), proteinuria (uri-
nary protein ≥3.5 g/24 h) was found in 10.0% of the lenva-
tinib and 0.0% of the placebo patients. We report a 23-year-
old patient with metastatic medullary thyroid cancer who 
was enrolled in the phase III trial, comparing cabozantinib to 
placebo and a 67-year-old patient with metastatic, papillary 
thyroid carcinoma who was undergoing treatment with len-
vatinib during his enrollment in the phase III trial. The first 
patient had a normal kidney function initially, but developed 
end-stage chronic kidney disease unexpectedly on cabozan-
tinib and additional zoledronate infusion. Whereas the sec-
ond patient suffered from a dramatic aggravation of his 
known mild chronic renal insufficiency (KDOQI stage 2) due 
to long standing hypertension and atherosclerosis during 
the treatment with lenvatinib. These severe AEs due to anti-
VEGF tyrosine kinase inhibitor treatment were unknown so 
far. In conclusion, these 2 cases argue for increased aware-
ness for the possibility of renal failure as a consequence of 
anti-VEFG treatment. Predisposing conditions like known 
mild chronic renal insufficiency with only mild proteinuria 
and with atherosclerosis or precipitating co-medications like 
zoledronate infusion need to be accounted for to prevent 
these severe AEs. © 2018 European Thyroid Association. 
Published by S. Karger AG, Basel
Introduction
Tyrosine kinase inhibitors (TKIs) have been ap-
proved as an important therapeutic option for the treat-
ment of progressive, metastatic medullary thyroid can-
cer (MTC) and radioiodine refractory differentiated 
thyroid cancer. For the treatment of MTC, cabozantinib 
was approved by the Food and Drug Administration in 
2012 and by the European Medicines Agency in 2014. 
Lenvatinib was accepted for the treatment of radioio-
dine refractory differentiated thyroid cancer by the Food 
and Drug Administration and European Medicines 
Agency in 2015. 
Adverse events (AEs) of all grades that were reported 
in ≥10.0% of the patients in a phase III study with cabo-
zantinib included diarrhea (63.1%), plamar-plantar 
erythrodysesthesia (50.0%), decreased weight (47.7%), 
decreased appetite (45.8%), nausea (43.0%), and fatigue 
(40.7%). Rare but potentially life-threatening AEs includ-
ing hemorrhage, gastrointestinal perforations, fistula de-
velopment were also observed. In 16.0% of patients, AEs 
led to the discontinuation of treatment. No AEs related to 
renal toxicity have been reported [1].
The lenvatinib phase III study reported treatment-re-
lated AEs of any grade in ≥10.0% of the patients includ-
ing: hypertension (67.8%), diarrhea (59.4%), fatigue or 
asthenia (59.0%), decreased appetite (50.2%), decreased 
weight (46.6%). AEs that led to treatment discontinuation 
were reported in 14.2% of patients receiving lenvatinib. 
Renal AEs were rare. However, renal failure, including 
acute renal failure of all grades, occurred in 4.2% of pa-
tients [2].
Both lenvatinib and cabozantinib are multikinase in-
hibitors with a strong VEGF signaling inhibition [3, 4]. 
Proteinuria is described as one of the most common renal 
side effects of other anti-VEGF drugs and frequently oc-
curs with hypertension [5]. 
In the lenvatinib phase III trial grade 3 (CTCAE), pro-
teinuria (urinary protein ≥3.5 g/24 h) was found in 10.0% 
of the lenvatinib and 0.0% of the placebo patients. A pro-
teinuria screening with dose reductions or treatment dis-
continuation in case of an overt proteinuria was part of 
this trial [2]. Based on clinical trials with pazopanib for 
renal cell carcinoma, Carhill et al. [6] have previously rec-
ommended that baseline renal function and urine analy-
sis in addition to periodic monitoring of renal function 
should be performed during the treatment with TKIs be-
cause of their potential to cause proteinuria. 
Here, we report one patient with initially normal kid-
ney function who unexpectedly developed chronic kid-
ney disease under cabozantinib treatment and a second 
patient who suffered from a dramatic aggravation of his 
known mild chronic renal insufficiency (KDOQI stage 2) 
under lenvatinib. This study is aimed at determining how 
this previously unknown but severe side effect of anti-
VEGF TKI treatment could be prevented in future.
First Patient
A 23-year-old patient with metastatic MTC was treated with 
4.4 GBq Y-90-DOTATE 10 months after surgery because of pro-
gressive MTC. Five months following treatment with 4.4 GBq Y-
90-DOTATE, the patient was enrolled in the phase III study com-
paring cabozantinib to placebo. He received blinded treatment for 
3 weeks. His creatinine was normal (62 μmol/L 30 days before the 
treatment, 66 μmol/L on the first day of the treatment). Also, he 
showed a normal estimated glomerular filtration rate (eGFR) of 
132.9 mL/min/1.73 m2 on the first day of the study treatment. Due 
to bone metastasis, the patient received 4 mg zoledronate twice. 
Shortly after a third zoledronate infusion, the patient developed 
vomiting which did not occur with prior zoledronate infusions 
before the initiation of the study treatment with cabozantinib. Six-
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teen days after his enrollment in the study and 11 days follow-
ing the third zoledronate treatment, a creatinine of 150.4 μmol/L 
and a hypoproteinemia was detected. His eGFR was 52 mL/
min/1.73 m2. Subsequently, the patient developed hyperkale-
mia (6.3 mmol/L), LDH of 525 U/L, anemia, thrombocytopenia 
(76/nL) and nephrotic range proteinuria of up to 25,415 mg/24 h. 
Renal biopsy on day 30 revealed severe diffuse glomerular throm-
botic microangiopathy of the VEGF-inhibitor associated type with 
podocyte damage. Although microangiopathic hemolytic anemia 
with thrombocytopenia ameliorated after 3 plasmapheresis treat-
ments, his renal function showed no improvement. The patient 
was discontinued from study treatment. Unfortunately, 4 months 
after initiating study treatment, the patient received his first hemo-
dialysis and died of progressive MTC 262 days after his enrollment 
in the study.
Second Patient
A 67-year-old patient with metastatic, papillary thyroid carci-
noma was treated with total thyroidectomy, followed by 3 radioio-
dine therapies with a total activity of 20 GBq. Because of progres-
sive radioiodine resistant disease 6 years after total thyroidectomy, 
the patient was enrolled in the double-blinded phase III study with 
lenvatinib versus placebo. Of note, the patient also suffered from 
long-term arterial hypertension and coronary heart disease with 
myocardial infarction 8 years before study inclusion. He presented 
a KDOQI stage 2 prior to the study introduction with an eGFR of 
71.09 mL/min/1.73 m2. There was spurious proteinuria assessed 
by a urine dip stix at study entry. Nevertheless, he fulfilled the 
study inclusion criteria and the criteria for the treatment with len-
vatinib. During the study, instable angina led to coronarography 
with stenting. During this and further coronarographies, he re-
ceived 140 mL of imeron 36 days after study entry and 46 mL of 
ultravist 370 on days 157 and 234 after study entry. Subsequently, 
the patient’s creatinine rose to 143 µmol/L. Renal ultrasonography 
determined kidney lengths of 9.8 and 9.7 cm most likely due to 
chronic (formerly inadequately controlled) long-term arterial hy-
pertension. His creatinine rose further to 218 µmol/L and his eGFR 
was 26.04 mL/min/1.73 m2 on day 281 after study entry. Therefore, 
lenvatinib was discontinued 279 days after study initiation. Serum 
creatinine declined to 142 µmol/L. After further applications of 
85 and 110 mL imeron for coronary angiography and femoral an-
gioplasty 59 and 131 days after discontinuation of lenvatinib, re-
spectively, his last creatinine was 177 µmol/L 264 days after discon-
tinuation of lenvatinib. The patient died because of a cerebral in-
farction 708 days after his enrollment in the study.
Discussion
A review of proteinuria-related anti VEGF side effects 
concluded that the most common renal side effects of an-
ti-VEGF drugs is proteinuria (range 21 up to 63%), which 
frequently occurs with hypertension [7]. Proteinuria has 
been described for several anti-VEGF agents [5, 7] and 
has also occurred during treatment with the recently ap-
proved TKI lenvatinib. Therefore, a drug class effect is 
highly likely.
To account for the known risk of renal AEs, protein-
uria screening has been recommended for anti-VEGF 
drugs [6] and was part of the lenvatinib phase III trial [2]. 
Our first patient had a normal renal function at study en-
try (KDOQI: stage 1, eGFR 132.9 mL/min/1.73 m2). Our 
second patient already presented with KDOQI stage 2 
(eGFR of 71.09 mL/min/1.73 m2). However, both devel-
oped chronic renal failure requiring dialysis and/or dis-
continuation of study treatment. Therefore, lack of sensi-
tivity of dip stick proteinuria assessment and serum cre-
atinine determination without the determination of the 
eGFR and protein differentiating analyses and other fac-
tors coprecipitating the renal damage in our 2 patients 
need to be considered before starting anti VEGF-TKI 
treatment. Patients with chronic kidney failure and 
planned TKI treatment are apparently at risk for further 
aggravation of renal failure.
Our first 23-year-old patient received 4 mg of zoledro-
nate 5 days after his enrollment in the phase III study be-
cause of bone metastasis. The incidence of proteinuria in 
patients receiving concurrent bevacizumab and pamidro-
nate was 33.9%, compared with 18.5% in patients without 
pamidronate in a phase III trial [8]. Moreover, zoledro-
nate has been associated with both dose-dependent and 
infusion time-dependent acute and chronic renal failures 
[9]. To reduce the risk of renal damage, 100 mL of 4 mg 
zoledronate should be infused over no less than 15 min 
[10]. After the third infusion of 4 mg zoledronate, our 
first patient experienced vomiting, which did not occur 
with prior zoledronate infusions. 
Bodmer et al. [9] reported a case of zoledronate-asso-
ciated renal failure with focal segmental glomerulosclero-
sis in a myeloma patient. Focal segmental glomeruloscle-
rosis has also been described during the treatment with 
pamidronate [11]. Other renal impairments attributable 
to zoledronate are zoledronate-associated toxic tubular 
necrosis, with the predominant pathological findings of 
tubular degenerative changes [10]. However, in our first 
patient the renal biopsy revealed severe diffuse glomeru-
lar thrombotic microangiopathy with podocyte damage. 
This histologic finding is not indicative of renal damage 
induced by zoledronate. However, severe diffuse glomer-
ular thrombotic microangiopathy with podocyte damage 
has been described in 6 patients treated with bevacizum-
ab [12] and is the pathognomonic histologic correlate in 
VEGF knock-out mice [12]. Therefore, this patient’s re-
nal damage is highly likely to be the consequence of the 
treat with an anti-VEGF agent. However, the only renal 
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AE in the cabozantinib phase III trial was proteinuria 
grade ≥3 in 0.9% and all grades in 1.9%. The only identi-
fiable precipitating cofactor in this young patient without 
any preexisting renal impairment is vomiting after zole-
dronate infusion immediately prior to the onset of renal 
damage. This did not occur after the previous 2 zoledro-
nate infusions. Therefore, this most likely indicates too 
fast infusion of zoledronate with possible blood pressure 
drop precipitating the anti-VEGF damage.
Our second patient already displayed initial signs of 
renal damage (KDOQI: stage 2, eGFR 71.09 mL/min/1.73 
m2) prior to anti-VEGF treatment with lenvatinib. He also 
had generalized atherosclerosis suggested by a myocardial 
infarction 8 years before study inclusion and femoral an-
gioplasty and ischemic cerebral infarction. Formerly, in-
adequately controlled long-term arterial hypertension 
most likely was the major contributing factor for all of 
these pathologies. These findings strongly suggest an in-
creased susceptibility for anti-VEGF adverse vascular 
events due to generalized atherosclerosis and chronic kid-
ney disease which in this patient manifested as an drastic 
aggravation of his mild renal failure due to a chronic kid-
ney disease of KDOQI of stage 4 (eGFR 26.78 mL/min/1.73 
m2). For this patient, the repeated angiographies must also 
be considered as a possible confounder or cofactor for the 
renal damage. However, diagnosis of contrast-induced 
nephropathy requires an absolute increase in serum cre-
atinine by ≥26.5 µmol/L from baseline within 48 h after 
contrast media application, or a relative increase in serum 
creatinine levels by ≥50% from baseline, or a urine output 
reduced to ≤0.5 mL/kg/h for at least 6 h [13]. Thus, in our 
patients’ case, the steady rise of serum creatinine 6 weeks 
after the last application of iodine-containing contrast 
media during treatment with lenvatinib is a strong indica-
tion of renal damage induced by a TKI (lenvatinib) with 
anti-VEGF receptor activity. However, it cannot be ex-
cluded that the concomitant application of imeron and 
ultravist together with lenvatinib could have led to an ad-
ditive or cumulative nephrotoxic effect.
In conclusion, these 2 cases argue for increased aware-
ness of the possibility that renal failure, as a consequence 
of anti-VEFG treatment, can occur in patients without 
proteinuria. Further predisposing or precipitating co-
medications or concomitant diseases like atherosclerosis 
need to be accounted for to prevent this AE as illustrated 
by these 2 case reports. Compulsory registries for AEs not 
reported in phase III trials and National Tumor Boards 
like TUTYREF [14] could help mitigate severe AEs to 
these rapidly evolving and expensive drugs. 
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TKIs including anti-VEGF receptor activity have been approved for the treatment of patients with radioiodine resistant thyroid
carcinomas. For lenvatinib arterial thromboembolic events are listed as adverse events of special interest with lenvatinib. In the
phase III study, arterial thromboembolic events were reported in 3% of lenvatinib-treated patients and 1% in the placebo group.
Most of the patients had predisposing factors. Only onemyocardial infarct was reported in the lenvatinib phase III study.We report a
73-year-old female patient withmetastatic thyroid papillary carcinomawhowas treatedwith total thyroidectomy.The operationwas
followed by four radioiodine therapies over a period of 6 years. At 6 years she developed lungmetastasis without radioiodine uptake,
one solitary liver metastasis and one solitary right renal metastasis. One year after the first diagnosis of radioiodine resistant lung
metastasis the lung metastasis showed progression according to RECIST criteria.This treatment was resulting in prolonged partial
response with disappearance of a hepatic and renal metastasis. A myocardial infarction occurred after 39 months of lenvatinib
treatment resulting in implantation of 3 stents and a two chamber pacemaker. The treatment was discontinued. Except for well
controlled hypertension there were neither predisposing diseases like diabetes nor symptoms of cardiac ischemia on exertion.
However, the family history for cardiovascular diseases was positive for cardiac infarction reported for one brother. Another brother
was treated for hypertension and the patient’smother suffered from a cerebral infarction at the age of 60.While only onemyocardial
infarct was reported in the lenvatinib phase III study with 392 patients this case suggests that long-term treatment with lenvatinib
may be associatedwith an increased risk for myocardial infarct also in patients with no predisposing diseases except well controlled
hypertension and positive family history for cardiovascular diseases.
1. Introduction
In 2015 lenvatinib, an inhibitor of vascular endothelial growth
factor receptors 1, 2, and 3, fibroblast growth factor receptors
1 through 4, platelet-derived growth factor receptor !, RET,
and KIT signaling networks [1, 2], has been approved by the
FDA and EMA for the treatment of radioiodine refractory
differentiated thyroid cancer.
A randomized, double-blinded phase III study involved
patients with progressive thyroid cancer that was refractory
to 131iodine and randomly assigned 261 patients to receive
lenvatinib (daily dose of 24 mg/d in 28-day cycles) and
131 patients to receive placebo. Compared with placebo,
lenvatinib was associated with significant improvements
in progression-free survival and the response rate among
patients with 131iodine-refractory thyroid cancer [3]. During
the 13.8months of median duration of treatment, treatment-
related adverse events (all grades) occurred in 97.3% in
the lenvatinib group; of these 75.9% were treatment-related
adverse events of grade 3 or higher [3]. In the SELECT trial
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3.0% of lenvatinib-treated patients presented arterial throm-
boembolic events. Most of the patients had cardiovascular
risk factors. Only one myocardial infarct was reported.
Here, we report a patient with papillary thyroid cancer
who suffered from a myocardial infarction during long-term
treatment with lenvatinib. This case cautions that long-term
treatment with lenvatinib can be associated with myocardial
infarction also in patients who were asymptomatic and had
no predisposing diseases except well controlled hypertension
and a positive family history for cardiovascular diseases.
2. Patient
We report a 73-year-old female patient with metastatic
thyroid papillary carcinoma who was treated with total thy-
roidectomy. The operation was followed by four radioiodine
therapies over a period of 6 years. At 6 years she developed
lung metastasis without radioiodine uptake, one solitary
liver metastasis and one solitary right renal metastasis. One
year after the first diagnosis of radioiodine resistant lung
metastasis the lung metastasis showed progression according
to RECIST criteria. The patient was therefore enrolled in the
phase III study comparing lenvatinib to placebo. After the
study ended the patient was unblinded. Lenvatinib treatment
resulted in prolonged partial response with disappearance of
the hepatic and renal metastasis. During further treatment
with lenvatinib with dose reduction from initially 24 to
10 mg at 17 months of lenvatinib treatment a myocardial
infarction occurred after 39 months of lenvatinib treatment
resulting in implantation of 3 stents and a two chamber
pacemaker. Treatment with lenvatinib was discontinued at
the time of diagnosis of the myocardial infarction. Except for
well controlled hypertension there were neither predisposing
diseases like diabetes nor symptoms of cardiac ischemia
on exertion. Quarterly repeated echocardiography at rest
showed normal results during the first two years of lenvatinib
treatment during the phase III study. However, the family
history for cardiovascular diseases was positive for cardiac
infarction reported for one brother. Another brother was
treated for hypertension and the patients’ mother suffered
from a cerebral infarction at the age of 60.
3. Discussion
Tyrosine kinase inhibitors with anti-VEGF receptor activity
are known for their potential to cause thromboembolic
adverse events.
Sorafenib, an inhibitor of VEGFR-1, VEGFR-2, and
VEGFR-3, RET (including RET/PTC translocations), RAF
(including BRAFV600E point mutation), and platelet-
derived growth factor receptor beta (PDGFR!) [4], was
approved for the treatment of radioiodine refractory DTC in
2014 by the EMA and FDA. Before it was also approved for
the treatment of unresectable hepatocellular carcinoma and
advanced renal-cell carcinoma.
A randomized, double-blind, placebo-controlled phase
III study involving patients with advanced clear-cell renal-
cell carcinoma reported cardiac ischemia or infarction in
12 patients in the sorafenib group (3%) and 2 patients
in the placebo group (<1%) (P=0.01). Of these events, 11
(including 2 deaths in the sorafenib group and 1 death in
the placebo group) were considered to be serious adverse
events associated with treatment [5]. A phase 3, double-
blinded, placebo-controlled study assigned 602 patients with
advanced hepatocellular carcinoma who had not received
previous systemic treatment to receive either sorafenib (at a
dose of 400 mg twice daily) or placebo. Cardiac Ischemia or
infarction appeared in 3% of the patients receiving sorafenib
compared to 1% in the placebo group [6]. The median
durations of sorafenib treatments in these studies were 10.6
months [4], 5.8months [5], and 5.3months [6].
Furthermore, soon after the introduction of bevacizum-
ab-treatment for metastatic breast cancer the clinical inci-
dence of arteriovascular events, i.e., cerebrovascular ischemia
was reported in 2% of the patients and 1.6% of the patients
suffering from heart failure and even more alarming 15%
having severe hypertension [7]. In addition, meta-analysis
showed that the addition of bevacicumab to chemotherapy
increased the risk of arterial thrombotic events when com-
pared to the chemotherapy alone [8]. Moreover a pooled
analysis of five randomized trials encompassing 1745 patients
randomly assigned to chemotherapy alone or chemotherapy
plus bevacicumab for the treatment of metastatic colorectal
cancer, breast cancer, and non-small-cell lung cancer showed
that the increase of arterial thromboembolic events (ATEs)
was further increased in elderly patients or patients with a
history of ATEs. Patients with both risk factors developed
ATEs in 17.9% [9].
A meta-analysis including 9711 patients from 19 ran-
domized controlled trials with bevacicumab [10] revealed an
overall incidence of ATEs of 1,5% whereof cardiac ischemia
(67,4%), CNS ischemia (7,9%), and cerebrovascular accident
(6,7%) were most common.The mortality of these ATEs was
8,2% [10].
Because of the thromboembolic potential of TKIs Conti
et al. proposed in 2013 a cardiovascular assessment of patients
undergoing a TKI treatment before treatment start and to
include patients at high/highest risk according to established
risk scores like the Global Registry of Acute Coronary Events
(GRACE) score in a cardiovascular monitoring program [11].
Recently, a multicenter phase 2 study of sunitinib another
antiangiogenic tyrosine kinase inhibitor in patients with
locally advanced or metastatic differentiated, anaplastic or
medullary thyroid carcinomas, revealed that during amedian
follow-up time of 9 months/25 months 14.1% of the patients
suffered from cardiac events [12]. Out of 5 deadly adverse
events 4 were cardiac events. Due to an expected increased
risk of severe adverse cardiac events the follow-up of the
study included systematic survey, a left ventricular ejec-
tion fraction (LVEF) ultrasound, and N-terminal probrain
natriuretic peptide or N-terminal brain natriuretic peptide
(probrain natriuretic peptide [BNP]/BNP) dosage. None of
these specific parameters showed the potential to select
patients more stringently [12].
Furthermore a meta-analysis on 4679 patients under
treatment with sorafenib or sunitinib or pazopanib demon-
strated an increased risk of fatal adverse events (RR 2.23)
regardless of tumor type and drug used, when compared with
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control groups. Myocardial infarction represented the cause
in 15% of all deaths attributable to VEGFR inhibitor [13].
Our case report suggests that lenvatinib should also be
added to the list of TKIs with ATE potential. So far, most
of the thromboembolic events appeared after short-term
treatment median duration of 10.8 months with tyrosine
kinase inhibitors and mostly in patients with predisposing
factors. However, our patient suffered from her first myocar-
dial infarction after long-term treatment with lenvatinib for
39 months, in absence of predisposing diseases except well
controlled hypertension and a positive family history for
cardiovascular diseases. These findings suggest that long-
term treatment with lenvatinib may be associated with
an increased risk for myocardial infarction. Therefore, as
previously proposed by Conti et al. for other TKIs also
patients with lenvatinib treatment should be assessed for
cardiovascular risk and coronary ischemia before and during
the treatment. However, as indicated by our patient not
only patients with high/very high cardiovascular risk factors
should be under closer clinical cardiovascular surveillance
as our patient’s GRACE score before study entry indicated
only a low individual risk of death by myocardial infarction.
The assessment of cardiovascular risk and coronary ischemia
should include a family history for cardiovascular diseases,
cardiac stress testing, and an initial and regular cardiac survey
to identify those at increased risk for cardiac events. It should
be performed before starting lenvatinib treatment and at
annual intervals during lenvatinib therapy. In addition, fur-
ther data on adverse events during long-term TKI treatment
with anti-VEGF receptor activity should be systematically
collected.
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3. Zusammenfassung  
3.1 Renal adverse events  
A review of proteinuria related anti VEGF side effects concluded that the most common renal 
side effects of anti-VEGF drugs is proteinuria (range 21% up to 63%) which frequently occurs 
with hypertension [10]. Proteinuria has been described for several anti-VEGF agents [10] [11] 
and has also occurred during treatment with the newly approved TKI lenvatinib. Therefore, a 
drug class effect is highly likely.  
To account for the known risk of renal adverse events proteinuria screening has been 
recommended for anti-VEGF drugs [12] and was part of the lenvatinib phase III trial [7].  Patient 
1 had a normal renal function at study entry (KDOQI: stadium 1, eGFR after CDK-EPI > 90ml/
min/1.73 m2). Patient 2 already presented with KDOQI stage 2 (eGFR (CDK-EPI) of 60 - 89 ml/
min/1.73 m2). However, both developed chronic renal failure requiring dialysis or 
discontinuation of study treatment. Therefore, lack of sensitivity of dip stic proteinuria 
assessment and serum creatinine determination without the determination of the eGFR and 
protein differentiating analyses and other factors coprecipitating the renal damage in our 2 
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patients need to be considered before starting anti VEGF-TKI treatment. Patients with chronic 
kidney failure and planned TKI-treatment are apparently at risk for further aggravation of renal 
failure.  
Patient 1 received 4 mg of zoledronate 5 days after his enrolment in the Phase III study because 
of bone metastasis. The incidence of proteinuria in patients receiving concurrent bevacicumab 
and pamidronate was 33.9%, compared with 18.5% in patients without pamidronate in a phase 
III trial [13]. Moreover, Zoledronate has been associated with both dose-dependent and infusion 
time-dependent acute and chronic renal failure [14]. In order to reduce the risk for renal damage, 
100 ml of 4 mg zolendronate should be infused over no less than 15 min [15]. After the 3rd 
infusion of 4mg zolendronate our 1st patient experienced vomiting, which did not occur with 
prior zolendronate infusions.  
Bodmer et al. reported a case of zoledronate-associated renal failure with focal segmental 
glomerulosclerosis (FSGS) in a myeloma patient [14]. FSGS has also been described during the 
treatment with pamidronate [16]. Other renal impairments attributable to zoledronate are 
zoledronate-associated toxic tubular necrosis, with the predominant pathological findings of 
tubular degenerative changes [15]. However, in our 1st patient the renal biopsy revealed severe 
diffuse glomerular thrombotic microangiopathy with podocyte damage. This histologic finding is 
not indicative of renal damage induced by zoledronate. However, severe diffuse glomerular 
thrombotic microangiopathy with podocyte damage has been described in 6 patients treated with 
bevacizumab [17] and is the pathognomonic histologic correlate in VEGF knock out mice [17]. 
Therefore this patient’s renal damage is highly likely to be the consequence of VEGF-Inhibition. 
However, the only renal adverse event in the Cabozantinib phase III trial was proteinuria grade ≥ 
3 in 0.9% and all grades in 1.9%. The only identifiable precipitating co-factor in this young 
patient without any preexisting renal impairment is his vomiting after zoledronate infusion 
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immediately prior to the onset of his renal damage. This did not occur after the previous 2 
zoledronate infusions. Therefore, this most likely indicates too fast infusion of zoledronate with 
possible blood pressure drop precipitating the anti VEGF damage.  
Patient 2 already displayed initial signs of renal damage (KDOQI: stage 2, eGFR (CDK-EPI) of 
60 - 89 ml/min/1.73 m2) prior to anti-VEGF treatment with lenvatinib. He also had generalised 
atherosclerosis suggested by a myocardial infarction 8 years before study inclusion and femoral 
angioplasty and ischemic cerebral infarction. Formerly inadequately controlled long term arterial 
hypertension most likely was the major contributing factor for all of these pathologies. These 
findings strongly suggest an increased susceptibility for anti-VEGF adverse vascular events due 
to generalised atherosclerosis and chronic kidney disease which in this patient manifested as an 
drastic aggravation of his mild renal failure to a chronic kidney disease of KDOQI of stadium 4 
(eGFR after CDK-EPI of 15 - 29 ml/min/1.73 m2). For this patient, the repeated angiographies 
must also be considered as a possible confounder or cofactor for the renal damage. However, 
contrast-induced nephropathy requires an absolute increase in serum creatinine by ≥ 26,5 µmol/l 
from baseline within 48 h after contrast media application, or a relative increase in serum 
creatinine levels by ≥ 50% from baseline, or a urine output reduced to ≤ 0.5 ml/kg/h for at least 6 
h [18]. Thus, in our patient, the steady further rise of serum creatinine 6 weeks after the last 
application of iodine containing contrast media during treatment with lenvatinib is a strong 
indication of renal damage induced by a TKI (lenvatinib) with anti-VEGF receptor activity. 
However, it cannot be excluded that the concomitant application of imeron and ultravist together 
with lenvatinib could have led to an additive or cumulative nephrotoxic effect.  
In conclusion these 2 cases argue for increased awareness for the possibility that renal failure, as 
a consequence of anti-VEFG treatment, can occur in patients without proteinuria. Further 
predisposing or precipitating co-medications or concomitant diseases like atherosclerosis need to 
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be accounted for in order to prevent this adverse event as illustrated by these 2 case reports. 
Compulsory registries for adverse events not reported in phase III trials and national tumour 
boards like TUTYREF [19] could help to mitigate severe adverse events to these rapidly 
evolving and expensive drugs.  
3.2 Cardiovascular adverse events  
Tyrosine kinase inhibitors with anti-VEGF receptor activity are known for their potential to 
cause thromboembolic adverse events. A randomised, double-blind, placebo-controlled phase III 
study involving patients with advanced clear-cell renal-cell carcinoma reported cardiac ischemia 
or infarction in 12 patients in the sorafenib group (3%) and 2 patients in the placebo group (<1%) 
(P=0.01). Of these events, 11 (including 2 deaths in the sorafenib group and 1 death in the 
placebo group) were considered to be serious adverse events associated with treatment [20]. A 
phase 3, double-blinded, placebo-controlled study assigned 602 patients with advanced 
hepatocellular carcinoma who had not received previous systemic treatment to receive either 
sorafenib (at a dose of 400 mg twice daily) or placebo. Cardiac Ischemia or infarction appeared 
in 3% of the patients receiving sorafenib compared to 1% in the placebo group [21]. The median 
duration of sorafenib treatments in these studies were 10.6 months [22], 5.8 months [20] and 5.3 
months [21].  
Because of the thromboembolic potential of TKIs Conti et al. proposed in 2013 a cardiovascular 
assessment of patients undergoing a TKI treatment before treatment start and to include patients 
at high/highest risk according to established risk scores like the Global Registry of Acute 
Coronary Events (GRACE) – score in a cardiovascular monitoring program [23].  
Recently, a multicenter phase 2 study of sunitinib another antiangiogenic tyrosine kinase 
inhibitor in patients with locally advanced or metastatic differentiated, anaplastic or medullary 
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thyroid carcinomas revealed that during a median follow-up time of 9 months/25 months 14.1% 
of the patients suffered from cardiac events [24]. Out of 5 deadly adverse events 4 were cardiac 
events. Due to an expected increased risk of severe adverse cardiac events the follow-up of the 
study included systematic survey, a left ventricular ejection fraction (LVEF) ultrasound and N-
terminal pro-brain natriuretic peptide or N-terminal brain natriuretic peptide (pro-brain 
natriuretic peptide [BNP]/BNP) dosage. None of these specific parameters showed the potential 
to select patients more stringently [24].  
A meta-analysis including 9711 patients from 19 randomised controlled trials with Bevacicumab 
revealed an overall incidence of ATEs of 1,5% whereof cardiac ischemia (67,4%), CNS ischemia 
(7,9%) and cerebrovascular accident (6,7%) were most common [25]. The mortality of these 
ATEs was 8,2% [25].  
The 3rd case report concerning cardiovascular adverse events suggests that lenvatinib should 
also be added to the list of TKIs with ATE potential. So far, most of the thromboembolic events 
appeared after short-term treatment median duration of 10.8 months with tyrosine kinase 
inhibitors and mostly in patients with predisposing factors. However, our patient suffered from 
her 1st myocardial infarction after long-term treatment with lenvatinib for 39 months, in absence 
of predisposing diseases except well controlled hypertension and a positive family history for 
cardiovascular diseases. These findings suggest that long-term treatment with lenvatinib may be 
associated with an increased risk for myocardial infarction. Therefore, and as previously 
proposed by Conti et al. for other TKIs also patients with lenvatinib treatment should be assessed 
for cardiovascular risk and coronary ischemia before and during the treatment. However, as 
indicated by our patient not only patients with high/very high cardiovascular risk factors should 
be under closer clinical cardiovascular surveillance as our patient’s GRACE score before study 
entry indicated only a low individual risk of death by myocardial infarction. The assessment of 
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cardiovascular risk and coronary ischemia should include a family history for cardiovascular 
diseases, cardiac stress testing and an initial and regular cardiac survey to identify those at 
increased risk for cardiac events. It should be performed before starting lenvatinib treatment and 
at annual intervals during lenvatinib therapy. In addition, further data on adverse events during 
long-term TKI treatment with anti-VEGF receptor activity should be systematically collected.  
  
 22
4. Literaturverzeichnis  
[1] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D M, Forman D, 
Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in 
GLOBOCAN 2012. International Journal of Cancer. 2014; doi.org/10.1002/ijc.29210 
[2] UpToDate, Inc. and/or its affiliates: „Differentiated Thyroid cancer“, unter: https://
www.uptodate.com/contents/differentiated-thyroid-cancer-overview-of-management?
search=thyroid%20cancer&source=search_result&selectedTitle=1~150&usage_type=default&di
splay_rank=1 (aufgerufen am 14.08.2019) 
[3] Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, 
Lumbroso JD, De Vathaire F, Schlumberger M: Long-term outcome of 444 patients with distant 
metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine 
therapy. J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9. Epub 2006 May 9.  
[4] UpToDate, Inc. and/or its affiliates: „Medullary thyroid cancer“, unter: https://
www.uptodate.com/contents/medullary-thyroid-cancer-clinical-manifestations-diagnosis-
a n d s t a g i n g ?
search=thyroid%20cancer&source=search_result&selectedTitle=8~150&usage_type=default&di
splay_rank=8 (aufgerufen am 14.08.2019) 
[5] UpToDate, Inc. and/or its affiliates: „Medullary thyroid cancer: Chemotherapy and 
immunotherapy“, unter: https://www.uptodate.com/contents/medullary-thyroid-cancer-
c h e m o t h e r a p y - a n d - i m m u n o t h e r a p y ?
search=thyroid%20cancer&source=search_result&selectedTitle=16~150&usage_type=default&
display_rank=16 (aufgerufen am 14.08.2019) 
 23
[6] Wells S A, Jr, Robinson B G, Gagel R F, Dralle H, Fagin J A, Santoro M, Baudin E, Elisei R, 
Jarzab B, Vasselli J R, Read J, Langmuir P, Ryan A J, Schlumberger M J . Vandetanib in Patients 
With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind 
Phase III Trial. J Clin Oncol. 2012 Jan 10; 30(2): 134–141. 
[7] Schlumberger M1, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, 
Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, 
Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI: Lenvatinib versus placebo in 
radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30 
[8] Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, 
Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, 
Nelkin B, Sherman SI: Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 
Oct 10;31(29):3639-46  
[9] Eisenhauera E.A., Therasseb P, Bogaertsc J, Schwartzd J.H., Sargente D, Fordf R, Danceyg J, 
Arbuckh S, Gwytheri S, Mooneyg M, Rubinsteing L, Shankarg L, Doddg L, Kaplanj R, 
Lacombec D, Verweijk J. New response evaluation criteria in solid tumours: Revised RECIST 
guideline (version 1.1). European Journal of Cancer 45. 2009; 228–247 
[10] Izzedine H1, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC: VEGF signalling 
inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010; 
46(2):439-48 
[11] Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G: Angiogenesis Inhibitor Therapies: 
Focus on Kidney Toxicity and Hypertension. Am J Kidney Dis 2007; 50: 203-18  
 24
[12] Carhill A, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, 
Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL: The non investigational use of 
tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and 
monitoring. J Clin Endocrinol Metab. 2013; 98(1):31-42  
[13] Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, 
Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS: Randomized phase III trial of 
capecitabine compared with bevacizumab plus capecitabine in patients with previously treated 
metastatic breast cancer. J Clin Oncol. 2005 Feb 1;23(4):792-9  
[14] Bodmer M, Amico P, Mihatsch MJ, Haschke M, Kummer O, Krähenbühl S, Mayr M: Focal 
segmental glomerulosclerosis associated with long-term treatment with zoledronate in a 
myeloma patient. Nephrol Dial Transplant. 2007 Aug;22(8):2366-70  
[15] Berenson J, Hirschberg R: Safety and convenience of a 15-minute infusion of zoledronic 
acid. Oncologist. 2005 Jan;10(1):82-3  
[16] Markowitz GS1, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch 
AD, D'Agati VD: Collapsing focal segmental glomerulosclerosis following treatment with high-
dose pamidronate. J Am Soc Nephrol. 2001 Jun;12(6):1164-72  
[17] Eremina V, Jefferson J.A, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, 
Kopp J.B, Kabir M, Backx P H, Ph.D., Gerber H-P., Ferrara N, Barisoni L, Alpers C, Quaggin S: 
VEGF Inhibition and Renal Thrombotic Microangiopathy. N Engl J Med. 2008 March 13; 358  
[18] Lakhal K, Ehrmann S, Chaari A, Laissy JP, Régnier B, Wolff M, Pajot O: Acute Kidney 
Injury Network definition of contrast-induced nephropathy in the critically ill: incidence and 
outcome. J Crit Care. 2011;26:593–599  
 25
[19] Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudet AL, Do 
Cao C, Chougnet CN, Leboulleux S, Baudin E, Schlumberger M, de la Fouchardière C: Tyrosine 
kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study 
of the TUTHYREF network. Eur J Endocrinol. 2014 Mar 8;170(4):575-82. doi: 10.1530/
EJE-13-0825.  
[20] Escudier B, Tim Eisen T, Stadler W M,Szczylik C, Oudard S, Siebels M, Negrier S, 
Chevreau C, Solska E, Desai A A, Rolland F, Demkow T, Hutson T E, Gore M, Freeman S, 
Schwartz B, Shan M, Simantov R, Bukowski R M. Sorafenib in Advanced Clear-Cell Renal- 
Cell Carcinoma. N Engl J Med. 2007;356:125-34  
[21] Llovet J M, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blan J-F, de Oliveira A C, Santoro A, 
Raoul J-L, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten T F, Galle P R, Seitz J-
F, Borbath I, Häussinger D, Gi- annaris T, Shan M, Moscovici M, M.D., Voliotis D, Bruix J. 
Sorafenib in Advanced Hepatocel- lular Carcinoma. N Engl J Med. 2008;359:378-90. 
[22] Brose M, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini 
F, Paschke R, KeeShong Y, Sherman SI, Smit J WA, Chung J, Kappeler C, Pena C, Molnár I, 
Schlumberger M J, and on behalf of the DECISION Investigators. Sorafenib in locally advan- 
ced or metastatic, radioactive iodine- refractory, differentiated thyroid cancer: a randomized, 
double- blind, phase 3 trial. Lancet. 2014 July 26; 384(9940): 319–328.  
[23] Elena C, Romiti A, Musumeci M B, Passerini J, Zezza L, Mastromarino V, D Á ntonio C, 
Marchetti P, Paneni F, Autore C, Volpe M. Aterial thrombotic events and acute coronary syn- 
dromes with cancer drugs: Are growth factors the missed link? What both cardiologist and on- 
cologist should know about novel angiogenesis inhobitores. International J of Cardiology. 2013; 
2421-2429  
 26
[24] Ravaud A, de la Fouchardie`re C , Caron P , Doussau A , Do Cao C , Asselineau J, Rodien P, 
Pouessel D, Nicolli-Sire P, Klein M, Bournaud-Salinas C, Wemeau J-L, Gimbert A, Picat M- Q, 
Pedenon D, Digue L, Daste A, Catargi B, Delord J-PA multicenter phase II study of sunitinib in 
patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid 
carcinomas: mature data from the THYSU study. European Journal of Cancer 76 (2017); 
110e117  
[25] Wei-Xiang Q, Zan Shen, Li-Na Tang, Yang Yao. Risk of arterial thromboembolic events 
with vascular andothelial growth factor receptor tyrosine kinase inhibitor: an up-to-date meta- 
analysis. Critical reviews in oncology/hematology. 2014; 71-82  
 27
5. Darstellung des eigenen Beitrags  
5.1 ETJ - Anti VEGF-TKI treatment and new renal adverse events not published in the 
phase III trial  
Titel: Anti VEGF-TKI treatment and new renal adverse events not published in the phase III trial  
Journal: European Thyroid Journal, DOI: 10. 1159/000491387  
Autoren: Luisa Paschke, PD Dr. Thomas Lincke, Dr. Katja Mühlberg, PD Dr. Wolfram Jabs, 
Prof. Dr. Tom Lindner, Prof. Dr. Ralf Paschke  
Anteil Luisa Paschke: Erstellen des Publikationsentwurfs und weitere Überarbeitung 
entsprechend der Revisionskommentare der Koautoren. Erstellung der kumulativen 
Dissertationsarbeit.  
Anteil PD Dr. Thomas Lincke: Überarbeitung und Diskussion nuklearmedizinischer Aspekte.  
Anteil Dr. Katja Mühlberg: Überarbeitung und Diskussion angiologischer und kardiologischer 
Aspekte des Manuskripts.  
Anteil PD Dr. Wolfram Jabs: Bereitstellung von Daten des klinischen Verlaufs im Vivantes 
Klinikum, Berlin.  
Anteil Prof. Dr. Tom Lindner: Diskussion und Revision nephrologischer Aspekte des 
Manuskripts. Konzipierung und Überarbeitung der Publikation.  
Anteil Prof. Dr. Ralf Paschke: Diskussion und Revision endokrinologischer und onkologischer 
Aspekte des Manuskripts. Konzipierung und Überarbeitung der Publikation.  
 28
5.2 Case reports in Endocrinology - Myocardial infarction after long term treatment with a 
tyrosine kinase inhibitor (TKI) with anti-VEGF receptor activity  
Titel: Myocardial infarction after long term treatment with a tyrosine kinase inhibitor (TKI) with 
anti-VEGF receptor activity  
Journal: Case reports in Endocrinology, DOI: 10.1155/2019/7927450 
Autoren: Luisa Paschke, PD Dr. Thomas Lincke, Dr. Katja Mühlberg, Prof. Dr. Tom Lindner, 
Prof. Dr. Ralf Paschke  
Anteil Luisa Paschke: Erstellung des Publikationsentwurfs und weitere Überarbeitung 
entsprechend der Revisionskommentare der Koautoren. Erstellung der kumulativen 
Dissertationsarbeit.  
Anteil PD Dr. Thomas Lincke: Überarbeitung und Diskussion nuklearmedizinischer Aspekte.  
Anteil Dr. Katja Mühlberg: Anteil Katja Mühlberg: Überarbeitung und Diskussion 
angiologischer und kardiologischer Aspekte des Manuskripts.  
Anteil Prof. Dr. Tom Lindner: Diskussion und Revision nephrologischer Aspekte des 
Manuskripts. Konzipierung und Überarbeitung der Publikation.  
Anteil Prof. Dr. Ralf Paschke: Diskussion und Revision endokrinologischer und onkologischer 
Aspekte des Manuskripts. Konzipierung und Überarbeitung Publikation 
 
 
  
 29
2. Gase reports in Endocrinology - Myocardial infarction after long term treatment with a
tyrosine kinase Inhibitor (TKI) with anti-VEGF receptor activity
Titel: Myocardial infarction aftcr long tcrm treatment with a tyrosine kinase inhibitor (TKI) with
anti-VEGF re eptor activity
Journal: Gase reports in Endocrinology, DOI: 10.1155/2019/7927450
Autoren: Luisa Paschke, FD Dr. Thomas Lincke, D . Katj  Mühlberg, Prof. Dr. Tom Lindner, Prof.
Dr. Ralf Paschke
Anteil Luisa Paschke: Erstellung des Publikationsentwurfs und weitere Überarbeitung entsprechend
der Revisionskommentare der Koautoren. Erstellung der kumulativen Dissertationsarbeit.
Anteil PD Dr. Thomas Lincke: Überarbeitung und Diskussion nuklearmedizinischer Aspekte.
Anteil Dr. Katja Mühlberg: Anteil Katja Mühlherg: Überarbeitung und Diskussion angiologiscber
und kardiologiscber Aspekte des Manuskripts.
Anteil Prof. Dr. Tom Lindner: Diskussion und Revision nepbrol giscber Aspekte des Manuskripts.
Konzipierung und Überarbeitung der Publikation.
Anteil Prof. Dr. Ralf Paschke: Diskussion und Revision endokrinologiscber und onkologiscber
Aspekte des Manuskripts. Konzipierung und Überarbeitung Publikation.
■;vu;ouri;ul<vLs!'\iiKliM LEIPZIG AöR
ffir Innere ft/Sodizlr!,
•JurolofJie rind Derma{o!ogifi "
:;9'?Ji'fj5nö?.kri.noIogJe undNephrc
• ür.Gekllon Neef
rologic
20; hSs röIiosLelJa'
Prof. Dr. T. H. Lindner Dr. K. Mühlberg
Prof. Dr. R. Paschke PD. Dr. T. Lincke
5.2 Case reports in Endocrinology - Myocardial infarction after long term treatment with a 
tyrosine kinase inhibitor (TKI) with anti-VEGF receptor activity 
Titel: Myocardial infarction after long term treatment with a tyrosine kinase inhibitor (TKI) with 
anti-VEGF r ceptor activity  
Journal: Case reports in Endocrinology, DOI: 10.1155/2019/7927450 
Autoren: Luisa Paschke, PD Dr. Thomas Lincke, Dr. Katja Mühlberg, Prof. Dr. Tom Lindner, Prof. 
Dr. Ralf Paschke  
Anteil Luisa Paschke: Erstellung des Publikationsentwurfs und weitere Überarbeitung entsprechend 
der Revisionskommentare der Koautoren. Erstellung der kumulativen Dissertationsarbeit.  
Anteil PD Dr. Thomas Lincke: Überarbeitung und Diskussion nuklearmedizinischer Aspekte.  
nteil r. Katja Mühlberg: Anteil Katja Mühlberg: Überarbeitung und Diskussion angiologischer 
und kardiologischer Aspekte des Manuskripts.  
Anteil Prof. Dr. Tom Lindner: Diskussion und Revision nephrologischer A pekte de  Manuskripts. 
Konzipierung und Überarbeitung der P blikation.  
Anteil Prof. Dr. Ralf Paschke: Diskussion und Revision endokrinologischer und onkologischer 
Aspekte des Manuskripts. Konzipierung und Überarbeitung Publikation.  
Prof. Dr. T. H. Lindner Dr. K. Mühlberg 
Prof. Dr. R. Paschke PD. Dr. T. Lincke  PD. Dr. W. Jabs  Luisa Paschke 
6.  Selbstständigkeitserklärung  
Erklärung über die eigenständige Abfassung der Arbeit  
Hiermit erkläre ich, dass ich die vorliegende Arbeit selbstständig und ohne unzulässige Hilfe 
oder Benutzung anderer als der angegebenen Hilfsmittel angefertigt habe. Ich versichere, dass 
Dritte von mir weder unmittelbar noch mittelbar eine Vergütung oder geldwerte Leistungen für 
Arbeiten erhalten haben, die im Zusammenhang mit dem Inhalt der vorgelegten Dissertation 
stehen, und dass die vorgelegte Arbeit weder im Inland noch im Ausland in gleicher oder 
ähnlicher Form einer anderen Prüfungsbehörde zum Zweck einer Promotion oder eines anderen 
Prüfungsverfahrens vorgelegt wurde. Alles aus anderen Quellen und von anderen Personen 
übernommene Material, das in der Arbeit verwendet wurde oder auf das direkt Bezug genommen 
wird, wurde als solches kenntlich gemacht. Insbesondere wurden alle Personen genannt, die 
direkt an der Entstehung der vorliegenden Arbeit beteiligt waren. Die aktuellen gesetzlichen 
Vorgaben in Bezug auf die Zulassung der klinischen Studien, die Bestimmungen des 
Tierschutzgesetzes, die Bestimmungen des Gentechnikgesetzes und die allgemeinen 
Datenschutzbestimmungen wurden eingehalten. Ich versichere, dass ich die Regelungen der 
Satzung der Universität Leipzig zur Sicherung guter wissenschaftlicher Praxis kenne und 
eingehalten habe. 
 
Datum:  8. Oktober 2019   Unterschrift:  
 30
PD. Dr. W. Jabs  Luisa Paschke 
7. Lebenslauf  
Luisa Paschke 
 
 *09.10.1990 in Mannheim  
Rosa-Luxemburg-Str. 54  
04315 Leipzig 
Tel.: 0176 32849536 
 
Email: luisapaschke@hotmail.de  
     Studium  
10/2010 - 05/2017   Georg-August-Universität Göttingen Studium der Humanmedizin  
    1. Staatsexamen 08/2012, Note gut  
     2. Staatsexamen 10/2015, Note gut  
     3. Staatsexamen 05/2017, Note gut  
    Klinische Erfahrung  
    Famulaturen  
03/2013   Famulatur Innere Medizin, Gemeinschaftspraxis Dr. Scherer, Ulm   
08/2013   Famulatur Emergency Medicine, Petaluma/San Francisco, USA   
12/2013   Famulatur Nephrologie/Urologie Lyon Sud, Frankreich (Erasmus)   
04/2014   Famulatur Endokrinologie und Nephrologie, Universitätsklinikum   
    Leipzig          
08/2014   Famulatur Allgemeinchirurgie Universitätsklinikum Leipzig  
 31
    Praktisches Jahr  
05/2016 - 09/2016  PJ Innere Medizin St. Elisabeth-Krankenhaus Leipzig  
09/2016 - 12/2016  PJ Pädiatrie Universitätsklinikum Göttingen  
12/2016 - 04/2017  PJ Chirurgie Centre Hospitalier Fort de France, Martinique  
     
    Facharztausbildung  
seit 01/2018  Ärztin in Weiterbildung, St.Elisabeth und St. Barbara Krankenhaus  
    Halle (Saale), Pädiatrie 
    Weiterbildung  
11/2018   Grundkurs EKG für Pädiater und Neonatologen  
02/2019    Pediatric intensive care unit (PICU), University of Calgary  
     
    Sprachkenntnisse  
    Muttersprache: Deutsch  
    Englisch (fließend)  
     Französisch (fließend)  
      
    Praktika und Nebenerwerbstätigkeiten  
10/2012-03/2013  HiWi Anatomie, Anleitung des Präparationskurses  
05-08/2013   Tutorin für Anatomie, Studentenkurse  
 32
    Schulbildung  
1996-2000   Grundschule Markkleeberg-West  
2000-2009   Rudolf-Hildebrand-Gymnasium,  Markkleeberg  
  
 
  
 
  
  
  
 33
8. Danksagung  
Mein Dank gilt besonders den nachfolgenden Personen, welche mich während der Bearbeitung 
meiner Dissertation unterstützt haben.  
Besonders bedanken möchte ich mich bei Herrn Prof. Dr. T. H. Lindner für konstruktive 
Anmerkungen und Kritik, besonders der nephrologischen Aspekte meiner Arbeit.  
Bedanken möchte ich mich außerdem für das Mitwirken der Ko - Autoren der beiden 
Publikationen. Somit vielen Dank an Frau Dr. K. Mühlberg, Herrn Prof. Dr. T. Lincke, und Herrn 
Prof. Dr. W. Jabs.  
Und zum Abschluss bedanke ich mich bei meiner Familie und besonders bei meinem Vater, Prof. 
Dr. R. Paschke, welcher mich immer wieder in meiner Arbeit bestärkt und motiviert hat.
 34
